To include your compound in the COVID-19 Resource Center, submit it here.

FDA rejects Replagal pain endpoint

Transkaryotic Therapies (TKTX) announced Wednesday that FDA has rejected data on the primary endpoint the company planned to use to support its application to market Replagal agalsidase alfa for Fabry disease. The company also said that third quarter European Replagal sales are below

Read the full 439 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE